1
Return

iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3–targeted tri-specific killer engager

delete2026-07-11
delete0
PRE
AI
J
Jian-Fang Ning *
Z
Zachary B Davis
Q
Qudsia Zeb
P
Peter Hinderlie
K
Katie Tuininga
L
Liangjun Wang
S
Shivani Chaudhary
Y
Young Vue
J
Jun Ma
S
Shan Zhu
Y
Ying Zhang
Z
Zachary J Seeman
K
Karl-Johan Malmberg
B
Bob Valamehr
D
David A Largaespada
N
Nicholas Zorko
M
Martin Felices
F
Frank Cichocki
J
Jeffrey S Miller *
C
Clark C Chen
DOI：10.1093/neuonc/noag154delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Glioblastoma is the most aggressive primary brain tumor, with poor prognosis and limited treatment options. Natural killer (NK) cell therapy is a promising immunotherapeutic strategy, yet its efficacy remains limited. We evaluated FT538, a clinical-grade NK product derived from induced pluripotent stem cells (iPSCs), in glioblastoma models.

Journal

N
Neuro-Oncology
IF:
13.4
Papers:
1.2W
Citations:
2.5W

Organization

F
fate therapeutics
Scholars:
5
Papers: 2
Citations: 0
O
Oslo University Hospital
Scholars:
1.4K
Papers: 599
Citations: 1.9W
U
university of minnesota
Scholars:
3.2K
Papers: 1.4K
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers